Qure.ai Appoints Chief Commercial Officer to Drive Global Expansion

Mercadante brings 25 years of experience in AI, medical devices, and med-tech, having held leadership roles at Abbott, Johnson & Johnson, GE, Terumo, and most recently, Rapid AI.

Qure.ai, a leading healthcare AI company, has appointed Jim Mercadante as Chief Commercial Officer to spearhead its global sales and business development strategy. Based in New York, Mercadante will lead efforts to strengthen the company’s market presence and drive further growth.

With deployments in over 90 countries, Qure.ai has experienced significant expansion in Asia, Africa, the Middle East, and Europe. The company is now focusing on increasing its footprint in North and South America, leveraging its expertise in AI and digital health tools.

Prashant Warier, Co-Founder and CEO of Qure.ai said, “We warmly welcome Jim Mercadante and look forward to his leadership to advance our global sales strategy, strengthen partnerships with healthcare providers and channel partners, plus optimize commercial operations for growth globally. He will be based in our USA office but travel extensively to advance our worldwide sales strategy, consolidate existing customer successes and optimise commercial operations.”

Mercadante brings 25 years of experience in AI, medical devices, and med-tech, having held leadership roles at Abbott, Johnson & Johnson, GE, Terumo, and most recently, Rapid AI.

Expressing enthusiasm, the newly appointed Chief Commercial Officer of Qure.ai, Jim Mercadante, stated, "Qure.ai stands out for its exceptional people, cutting-edge technology, and clear vision for the future of healthcare. I’m excited to contribute to the company’s growth as we continue to expand globally and develop AI solutions that address critical healthcare challenges." His extensive background in commercial leadership and strategic marketing will support Qure.ai’s ongoing growth, following its recent Series D funding. The funding aims to fuel expansion across the US. and other regions, foster innovation in AI solutions, and explore strategic acquisitions.

Founded in 2016 by Prashant Warier, Qure.ai utilizes AI technology in over 3,000 imaging sites across 90 countries to assist in detecting diseases such as tuberculosis, lung cancer, and stroke.

Recently, the leading AI diagnostics company raised $65 million in a Series D funding round led by Lightspeed Venture Partners. The fresh infusion of funds sought to drive the expansion of Qure.ai's AI-powered healthcare diagnostics solutions in global markets, especially the US.

The startup aims to enhance its generative AI models and pursue acquisitions to strengthen its capabilities in disease detection.

Other participants in the funding round include 360 ONE Asset Management, Merck Global Health Innovation Fund, and Kae Capital, along with existing investors Novo Holdings, Health Quad, and TeamFund.

Stay tuned for more such updates on Digital Health News.